Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study

ConclusionEven though there was no improvement in ECOG index, this study did identify an increase of Hb for patients receiving FCM, indicating its potential benefit in iron-deficient cancer patients.

https://link.springer.com/10.1007/s00520-018-4250-x

Source: Supportive Care in Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: research